Register for October 9, 2018 Webinar


Science & Innovation Theater Webinar 


A Treatment for Moderate to Severe Opioid Use Disorder
Sponsored by Indivior

Tuesday, October 9, 2018, 2-3pm EDT

The objective of this webinar is to understand the efficacy and safety of a once-monthly buprenorphine injection delivering sustained therapeutic plasma concentrations for the treatment of moderate to severe opioid use disorder.

We will:

  • Review the opioid public health crisis
  • Examine the mechanism of action of buprenorphine
  • Discuss the SUBLOCADE™ blockade study
  • Summarize the efficacy and safety of SUBLOCADE™ for the treatment of opioid use disorder
  • Identify clinical considerations for the administration of SUBLOCADE™


  • Brent Davis Staton, MS, MD

This webinar is sponsored, developed and presented by the sponsor.  The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy. 

Sponsored by:  

   Indivior Logo 

** IMPORTANT: AMCP webinars are limited to the first 500 that join the webinar. However, AMCP will provide a link to the recording and slides to all registrants within a week from the webinar date. The recording and slides of sponsored webinars will be provided if permitted by the sponsor. 

For individuals from the media/press who are interested in attending, please contact Neal Learner at for more information.